TradingKey

关于 Scholar Rock Holding Corp 公司

Scholar Rock Holding Corporation 是一家生物制药公司。该公司专注于发现、开发和提供用于治疗严重疾病的药物，其中蛋白质生长因子的信号传导起着根本性的作用。其转化生长因子β (TGFb) 超家族生物学、其生长因子激活的新型分子机制使该公司能够开发专有平台，用于开发局部和选择性靶向前体的单克隆抗体。其候选产品 apitegromab 是一种选择性、完全人源化单克隆抗体，其作用机制可抑制骨骼肌中生长因子肌生长抑制素的激活。Apitegromab 正在开发为首个用于治疗脊髓性肌萎缩症 (SMA) 的肌肉靶向疗法。其另一个候选产品 SRK-181 是一种选择性抑制潜伏性 TGFb 激活的抑制剂，正在开发用于治疗癌症。

公司简介

公司代码SRRK

公司名称Scholar Rock Holding Corp

上市日期May 24, 2018

CEOMr. David L. Hallal

员工数量196

证券类型Ordinary Share

年结日May 24

公司地址301 Binney Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编02142

电话18572593860

网址https://scholarrock.com/

公司代码SRRK

上市日期May 24, 2018

CEOMr. David L. Hallal

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. David L. Hallal

Chairman of the Board, Chief Executive Officer

1.80M

+493.27%

Dr. Akshay K. Vaishnaw, M.D., Ph.D.

President - Research & Development, Director

616.21K

-1.08%

Mr. Vikas Sinha, CPA

Chief Financial Officer

600.00K

--

Ms. Caryn Parlavecchio

Chief Human Resources Officer

157.64K

-3.78%

Ms. Junlin Ho, J.D.

General Counsel, Corporate Secretary

96.29K

+1.19%

Ms. Tracey Sacco

Chief Commercial Officer

22.46K

--

Ms. Kristina M. Burow

Independent Director

21.07K

+11.85%

Ms. Katie Peng

Independent Director

19.27K

-13.59%

Dr. Mo Qatanani, Ph.D.

Chief Scientific Officer

16.59K

-18.11%

Mr. Joshua Reed

Independent Director

15.73K

+16.53%

名称

名称/职务

职务

持股

持股变动

Mr. David L. Hallal

Chairman of the Board, Chief Executive Officer

1.80M

+493.27%

Dr. Akshay K. Vaishnaw, M.D., Ph.D.

President - Research & Development, Director

616.21K

-1.08%

Mr. Vikas Sinha, CPA

Chief Financial Officer

600.00K

--

Ms. Caryn Parlavecchio

Chief Human Resources Officer

157.64K

-3.78%

Ms. Junlin Ho, J.D.

General Counsel, Corporate Secretary

96.29K

+1.19%

Ms. Tracey Sacco

Chief Commercial Officer

22.46K

--

收入明细

FY2024

暂无数据

地区USD

名称

营收

占比

United States

0.00

0.00%

业务

地区

暂无数据

股东统计

更新时间: 5月16日周五

持股股东

股东类型

持股股东

占比

Fidelity Management & Research Company LLC

14.48%

Invus Public Equities Advisors, LLC

9.74%

T. Rowe Price Associates, Inc.

9.27%

BlackRock Institutional Trust Company, N.A.

6.35%

Samsara BioCapital, LLC

5.91%

Other

54.24%

持股股东

占比

Fidelity Management & Research Company LLC

14.48%

Invus Public Equities Advisors, LLC

9.74%

T. Rowe Price Associates, Inc.

9.27%

BlackRock Institutional Trust Company, N.A.

6.35%

Samsara BioCapital, LLC

5.91%

Other

54.24%

股东类型

持股股东

占比

Investment Advisor

61.46%

Investment Advisor/Hedge Fund

26.29%

Hedge Fund

12.66%

Venture Capital

12.08%

Individual Investor

4.54%

Research Firm

2.75%

Sovereign Wealth Fund

2.10%

Pension Fund

1.07%

Private Equity

0.32%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

464

118.51M

124.82%

+4.05M

2025Q1

456

113.90M

119.97%

-666.42K

2024Q4

421

111.65M

118.02%

+13.32M

2024Q3

371

94.78M

117.45%

-2.79M

2024Q2

357

92.97M

115.37%

-3.23M

2024Q1

328

91.48M

116.64%

-131.69K

2023Q4

308

87.39M

122.16%

+15.93M

2023Q3

283

62.18M

111.86%

-162.68K

2023Q2

284

59.23M

108.43%

+2.68M

2023Q1

299

54.63M

105.29%

-1.64M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

13.75M

14.48%

+159.23K

+1.17%

Mar 31, 2025

Invus Public Equities Advisors, LLC

9.25M

9.74%

--

Mar 31, 2025

T. Rowe Price Associates, Inc.

8.81M

9.27%

-395.30K

-4.30%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.03M

6.35%

+96.10K

+1.62%

Mar 31, 2025

Samsara BioCapital, LLC

5.61M

5.91%

--

Mar 31, 2025

The Vanguard Group, Inc.

4.83M

5.09%

+98.76K

+2.09%

Mar 31, 2025

Redmile Group, LLC

4.40M

4.63%

-151.60K

-3.33%

Mar 31, 2025

State Street Global Advisors (US)

3.13M

3.3%

+494.85K

+18.75%

Mar 31, 2025

Eventide Asset Management, LLC

2.66M

2.8%

+2.37K

+0.09%

Mar 31, 2025

Polar Capital LLP

2.58M

2.72%

-125.00K

-4.62%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

iShares Neuroscience and Healthcare ETF

4.55%

Roundhill GLP-1 & Weight Loss ETF

2.23%

Tema Neuroscience and Mental Health ETF

1.45%

Virtus LifeSci Biotech Clinical Trials ETF

0.96%

SPDR S&P Biotech ETF

0.9%

Tema Heart & Health ETF

0.61%

Direxion Daily S&P Biotech Bull 3X Shares

0.51%

First Trust NASDAQ Pharmaceuticals ETF

0.51%

ProShares Ultra Nasdaq Biotechnology

0.37%

Invesco Nasdaq Biotechnology ETF

0.37%

iShares Neuroscience and Healthcare ETF

占比4.55%

Roundhill GLP-1 & Weight Loss ETF

占比2.23%

Tema Neuroscience and Mental Health ETF

占比1.45%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.96%

SPDR S&P Biotech ETF

占比0.9%

Tema Heart & Health ETF

占比0.61%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.51%

First Trust NASDAQ Pharmaceuticals ETF

占比0.51%

ProShares Ultra Nasdaq Biotechnology

占比0.37%

Invesco Nasdaq Biotechnology ETF

占比0.37%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Scholar Rock Holding Corp

36.520USD

Scholar Rock Holding Corp

36.520

概览

公司

财务